{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:51:21Z","timestamp":1788522681284,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/ijc.ijc_380_17","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T05:14:22Z","timestamp":1560748462000},"page":"626","source":"Crossref","is-referenced-by-count":4,"title":["First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience"],"prefix":"10.4103","volume":"54","author":[{"given":"Tamojit","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AH","family":"Rudresha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KC","family":"Lakshmaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GovindK","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Lokanatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LinuAbraham","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MC","family":"Suresh Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KN","family":"Lokesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LK","family":"Rajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.237894-1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0019-509X.237894-2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.juro.2009.12.035","article-title":"Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma","author":"Leibovich","year":"2010","journal-title":"J Urol"},{"key":"key-10.4103\/0019-509X.237894-3","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/1097-0142(20000801)89:3<604::AID-CNCR16>3.0.CO;2-Q","article-title":"Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors","author":"Moch","year":"2000","journal-title":"Cancer"},{"key":"key-10.4103\/0019-509X.237894-4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"key-10.4103\/0019-509X.237894-5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"key":"key-10.4103\/0019-509X.237894-6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.237894-7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/annonc\/mdi002","article-title":"Renal cell carcinoma: Review of novel single-agent therapeutics and combination regimens","author":"Amato","year":"2005","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.237894-8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","author":"Janzen","year":"2003","journal-title":"Urol Clin North Am"},{"key":"key-10.4103\/0019-509X.237894-9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","article-title":"Novel approaches in the therapy of metastatic renal cell carcinoma","author":"Lam","year":"2005","journal-title":"World J Urol"},{"key":"key-10.4103\/0019-509X.237894-10","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma.Groupe fran\u00e7ais d'immunoth\u00e9rapie","author":"Negrier","year":"1998","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.237894-11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/excr.2000.5139","article-title":"The von Hippel-Lindau tumor suppressor gene","author":"Kondo","year":"2001","journal-title":"Exp Cell Res"},{"key":"key-10.4103\/0019-509X.237894-12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.237894-13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.237894-14","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.237894-15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.237894-16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: Final overall survival results and safety update","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0019-509X.237894-17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.237894-18","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib versus sunitinib","author":"Motzer","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.237894-19","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.237894-20","first-page":"268","article-title":"Sunitinib in metastatic renal cell carcinoma: A single-center experience","author":"Krishna","year":"2013","journal-title":"Indian J Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0019-509X","issn-type":"print"},{"key":"key-10.4103\/0019-509X.237894-21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0019-509X.180844","article-title":"Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety","author":"Patel","year":"2016","journal-title":"Indian J Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0019-509X","issn-type":"print"},{"key":"key-10.4103\/0019-509X.237894-22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000330361","article-title":"Sunitinib for Asian patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles","author":"Kim","year":"2011","journal-title":"Oncology"},{"key":"key-10.4103\/0019-509X.237894-23","first-page":"2920","article-title":"Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma","author":"Li","year":"2011","journal-title":"Chin Med J (Engl)"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:40:55Z","timestamp":1786732855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_380_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"alternative-id":["237894"],"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_380_17","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}